Key result
Anticoagulant therapy is linked to improved survival in primary pulmonary hypertension.
Why the study?
The natural history and pathogenetic mechanisms of primary pulmonary hypertension were not well understood, including the role of thrombosis.
Does anticoagulant therapy improve survival in patients with primary pulmonary hypertension?
Cohort (n=120)
Does anticoagulant therapy improve survival in patients with primary pulmonary hypertension?
In patients with primary pulmonary hypertension, long-term survival is poor, but anticoagulant therapy and pulmonary arterial oxygen saturation are significant prognostic factors.
Poor 5-year survival (21%) in primary pulmonary hypertension warrants close monitoring; leaves open optimal risk stratification and therapies.
A long-term retrospective follow-up study was made of 120 patients (33 male, 87 female patients) with primary pulmonary hypertension--diagnosed by strict clinical and hemodynamic criteria--to obtain a better understanding of the natural history and possible pathogenetic mechanisms of the disease. The mean age at diagnosis was 34 (3 to 64) years, but only 24 patients (21%) remained alive 5 years later. Lung tissue obtained at autopsy from 56 patients revealed two major pathologic types: thromboembolic pulmonary hypertension in 32 patients (57%) and plexogenic pulmonary arteriopathy in 18 (32%). Thus, in more than half the patients undergoing autopsy the major histologic feature was thrombi without any evidence of plexiform lesions. The two groups were similar with respect to their clinical and hemodynamic features and short survival. Of the variables tested for prognostic importance by stepwise multivariate analysis, only two were significant: pulmonary arterial oxygen saturation (p less than .00001) and anticoagulant therapy (p = .01). Anticoagulant therapy is recommended for patients with primary pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Fuster et al. (1984) conducted a cohort in Primary pulmonary hypertension (n=120). Anticoagulant therapy and pulmonary arterial oxygen saturation was evaluated on Prognostic importance for survival (p=0.01). Anticoagulant therapy (p=0.01) and pulmonary arterial oxygen saturation (p<0.00001) were the only significant prognostic variables in patients with primary pulmonary hypertension.
Synapse has enriched 5 related papers. Consider them for comparative context: